13,321 reports of this reaction
10.5% of all RUXOLITINIB reports
#1 most reported adverse reaction
OFF LABEL USE is the #1 most commonly reported adverse reaction for RUXOLITINIB, manufactured by Incyte Corporation. There are 13,321 FDA adverse event reports linking RUXOLITINIB to OFF LABEL USE. This represents approximately 10.5% of all 126,373 adverse event reports for this drug.
RUXOLITINIB has an overall safety score of 85 out of 100. Patients taking RUXOLITINIB who experience off label use should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OFF LABEL USE is a frequently reported adverse event for RUXOLITINIB, accounting for a significant proportion of all reports.
In addition to off label use, the following adverse reactions have been reported for RUXOLITINIB:
The following drugs have also been linked to off label use in FDA adverse event reports:
OFF LABEL USE has been reported as an adverse event in 13,321 FDA reports for RUXOLITINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
OFF LABEL USE accounts for approximately 10.5% of all adverse event reports for RUXOLITINIB, making it one of the most commonly reported side effect.
If you experience off label use while taking RUXOLITINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.